Loading…
Loading the latest PSX data…
Loading the latest PSX data…
Highnoon Laboratories Limited (HINOON), GlaxoSmithKline Pakistan Limited (GLAXO), Abbott Laboratories (Pakistan) Limited (ABOT): performance, valuation, growth, risk and danioPSX score, side by side.
Add a stock
Growth of Rs 100 from 2025-11-12
Daily closes from PSX end-of-day files, adjusted for bonus shares, right issues and splits (not for cash dividends). KSE-100: official closes where available, otherwise rebuilt from its constituents.
| Measure | HINOONPharmaceuticals | GLAXOPharmaceuticals | ABOTPharmaceuticals |
|---|---|---|---|
| danioPSX score | 78 | 87 | 81 |
| Price and size | |||
| Price | Rs 965.26 | Rs 333.18 | Rs 1,005.70 |
| Today | +0.89% | −1.89% | +0.18% |
| Market cap | Rs 51.1bn | Rs 106.1bn | Rs 98.5bn |
| Traded per day | Rs 11m | Rs 51m | Rs 15m |
| Valuation and dividends | |||
| P/E | 12.4 | 9.7 | 10.6 |
| Dividend yield | 5.4% | 6.1% | 4.4% |
| EPS (last year) | Rs 77.75 | Rs 31.48 | Rs 81.37 |
| Business | |||
| EPS growth | +26.6% | +53.4% | +52.2% |
| Sales growth | +11.2% | +7.7% | +10.6% |
| Net margin | 16.0% | 15.2% | 10.6% |
| Returns | |||
| 1 month | +3.6% | +6.6% | +6.5% |
| 3 months | −2.4% | −2.9% | +12.1% |
| 1 year | −14.3% | −15.4% | −7.6% |
| vs KSE-100, 1 year | -25.2 pts | -26.3 pts | -18.5 pts |
| Trend and risk | |||
| 52-week position | 55% | 24% | 41% |
| RSI 14 | 59 | 57 | 67 |
| RS rank | 44 | 39 | 68 |
| Volatility | 31% | 34% | 30% |
| Beta | 0.71 | 1.06 | 0.77 |
| danioPSX score | |||
| Value | 42 | 69 | 61 |
| Quality | 78 | 81 | 74 |
| Dividend | 59 | 64 | 34 |
| Momentum | 46 | 34 | 61 |
| Safety | 74 | 80 | 76 |
| Shariah-compliant | Yes | Yes | Yes |
Bold marks the best value in each row where higher (or, for P/E and volatility, lower) is clearly better.
A comparison of published numbers, not a recommendation. Share this page: the address holds the stocks. Find more stocks with the screener